Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02984566 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)

Study acronym: TROG1703 LARK
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 19, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Jan 2026 to Jul 2026v14
  2. Primary completion date: Jul 2025 to Jan 2026
    • Study completion date: Dec 2025 to Jan 2026
    v13
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 46 to confirmed 32
    • Site details revised at 4 of 4 sites
    v12
  4. Primary completion date: Jul 2023 to Jul 2025
    • Study completion date: Dec 2024 to Dec 2025
    v11
  5. Primary completion date: Mar 2022 to Jul 2023
    • Study sites: 1 to 4
    • Study completion date: Dec 2022 to Dec 2024
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. Primary completion date: Mar 2021 to Mar 2022
    • Study completion date: Mar 2021 to Dec 2022
    v9
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2019 to Jan 14, 2020
    v8
  3. Start date: Oct 2019 to Dec 2019
    • Primary endpoint revised
    • Secondary endpoints: 8 to 9
    v7
  4. Start date: Jan 2019 to Oct 2019v6
  5. Start date: Jun 2018 to Jan 2019v5
  6. Start date: Mar 2018 to Jun 2018v4
  7. Start date: Mar 2017 to Mar 2018v3
  8. Start date: Jan 2017 to Mar 2017
    • Eligibility criteria expanded, about 23 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Sydney
35 trials monitored
See 1 trial at risk
Liver Cancer
1,598 trials monitored
See 71 trials at risk
Primary and secondary liver cancer patients will receive liver SABR with or without KIM intervention.
Trial Details
NCT Number NCT02984566
Lead Sponsor University of Sydney
Conditions
(from sponsor)		 Liver Cancer
Related terms Carcinoma, Hepatocellular, Liver Neoplasms
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov